VE 16084
Alternative Names: VE-16,084; VE-16,084 (irreversible peptidyl ICE inhibitor) - VertexLatest Information Update: 19 May 2011
At a glance
- Originator Vertex Pharmaceuticals
- Class Antirheumatics
- Mechanism of Action Caspase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 19 May 2011 Discontinued - Preclinical for Rheumatic disorders in USA (unspecified route)
- 23 Jul 1998 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
- 22 Nov 1995 Preclinical development for Rheumatic disorders in USA (Unknown route)